fructosamine has been researched along with losartan potassium in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Atkin, SL; Bhandari, S; Cooke, M; Cox, H; Kilpatrick, ES; Konya, J; Lewis, N; Ng, JM | 1 |
| Barinka, F; Beckmann, J; Busch, V; Ebert, T; Lindner, TH; Rasche, FM; Rasche, WG; Schiekofer, S; Schneider, JG | 1 |
| Abdel Hamid, DZ; Mostafa, TM; Nienaa, YA | 1 |
2 trial(s) available for fructosamine and losartan potassium
| Article | Year |
|---|---|
Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Diabetic Nephropathies; Epoetin Alfa; Erythropoietin; Female; Fructosamine; Glycated Hemoglobin; Hematinics; Humans; Male; Middle Aged; Polyethylene Glycols; Renal Dialysis; Renal Insufficiency, Chronic | 2017 |
Alpha-lipoic acid improved anemia, erythropoietin resistance, maintained glycemic control, and reduced cardiovascular risk in diabetic patients on hemodialysis: a multi-center prospective randomized controlled study.
Topics: Anemia; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Erythropoietin; Fructosamine; Glycated Hemoglobin; Glycemic Control; Heart Disease Risk Factors; Humans; Iron; Prospective Studies; Renal Dialysis; Risk Factors; Thioctic Acid; Tumor Necrosis Factor-alpha; Urea | 2022 |
1 other study(ies) available for fructosamine and losartan potassium
| Article | Year |
|---|---|
Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.
Topics: Administration, Intravenous; Aged; Biomarkers; Blood Glucose; Delivery of Health Care; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Epoetin Alfa; Erythropoietin; Female; Follow-Up Studies; Fructosamine; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Hematinics; Humans; Iron; Male; Monitoring, Physiologic; Prospective Studies; Recombinant Proteins; Renal Insufficiency, Chronic; Serum Albumin; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |